Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Annual Meeting’s Message: Stand Tall, But Gaze Past Your Navel

Executive Summary

DANA POINT, Calif. - A mood of resolute pride saturated the 50th annual meeting of the Pharmaceutical Research and Manufacturers of America, where speakers and panelists stressed the industry's eventual return to its once-bright public image by spreading the news about what they said is the biggest factor pushing up costs of medical care in the developed world: treatment of chronic diseases, especially those caused by obesity

You may also be interested in...



PhRMA cosponsors health policy conference series

Rising rates of chronic medical conditions is the topic of a July 31 conference convened by the Center for Studying Health System Change and sponsored by the Pharmaceutical Research and Manufacturers of America, the American College of Preventive Medicine and DMAA: The Care Continuum Alliance. Chronic illness was the theme of PhRMA's most recent annual meeting (1"The Pink Sheet," April 7, 2008, p. 15). The upcoming session, to be held in Washington, D.C. will consider the growing prevalence of chronic health conditions, and resulting costs, consequences and need for preventive strategies. It is the first of four policy conferences; future topics include value-based health benefit structures

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel